D-1260-2020 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1260-2020 was initiated by Teva Pharmaceuticals USA on Mar 5, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number that shares the same component. The recall status is terminated (terminated Nov 19, 2020). Affected quantity: 600 cartons/2 auto-injector per carton.

Recall details

Product Type
Drugs
Report Date
May 13, 2020
Initiation Date
Mar 5, 2020
Termination Date
Nov 19, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
600 cartons/2 auto-injector per carton

Product description

Epinephrine Injection USP, 0.3 mg (Auto-Injector), 0.3 mg/ 0.3 mL pre-filled syringe, Rx Only, Manufactured for Teva Pharmaceuticals USA, Inc. North Wales, PA 19454. NDC 0093-5986-27

Reason for recall

CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number that shares the same component.

Distribution pattern

Product was distributed to 1 wholesaler who still had all units within their possession and had not shipped or further distributed any of the product.

Code information

Lot # 007F19AA, exp. date 04/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1260-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1260-2020. Report a data issue: hello@regdatalab.com.